Revenue segments as reported by the company.

U.S. Pharmaceutical

Prescription Technology Solutions

Medical-Surgical Solutions

International

Corporate

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, distribution, general, and administrative expenses

Claims and litigation charges, net

Restructuring, impairment, and related charges, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

McKesson

McKesson Corp. engages in the provision of supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology. It operates through the following segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products, provides practice management, technology, clinical support, and business solutions to community-based oncology, and other specialty practices, and sells financial, operational, and clinical solutions to pharmacies and provides consulting, outsourcing, technological, and other services. The International segment provides distribution and services to wholesale, institutional, and retail customers in European countries and Canada. The Medical-Surgical Solutions segment offers medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. The RxTS segment brings together CoverMyMeds, RelayHealth, RxCrossroads, and McKesson Prescription Automation, including Multi-Client Central Fill as a Service, to serve biopharma and life sciences partners and patients. The company was founded by John McKesson and Charles Olcott in 1833 and is headquartered in Irving, TX.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

McKesson reports robust fiscal 2023 performance and focuses on sustainability

McKesson's Q4 fiscal 2023 earnings call highlighted strong financial performance, strategic priorities, and a focus on sustainability and employee recognition. The company faces challenges related to operational efficiencies and managing potential impacts from industry dynamics. However, it remains optimistic about opportunities for long-term growth and partnerships in the oncology space.

McKesson reports strong Q1 performance and anticipates sustained growth

McKesson's Q1 fiscal 2024 earnings call showcased strong financial performance, with a focus on prescription volume growth and expansion in the U.S. Oncology Network. The company faces potential fluctuations and timing challenges in its RxTS business but expects to benefit from volume-related factors and continual development. Overall, McKesson is well-positioned for sustainable growth and value creation.

McKesson excels in Q3, eyes oncology growth and sustainability

McKesson's Q3 performance was strong, with raised guidance and progress in strategic priorities.
The company's strengths lie in its focus on oncology, sustainability initiatives, and operational performance.
Challenges include macroeconomic factors, biosimilar management, and margin improvement strategies.
Opportunities in oncology growth, biosimilars, and strategic partnerships pave the way for future success.

McKesson reports robust earnings, poised for sustainable growth in healthcare

McKesson's Q4 2023 earnings call highlighted strong financial performance, strategic advancements, and a commitment to driving sustainable growth in key healthcare segments.
The company's focus on efficiency, sustainability, and employee engagement underpins its competitive strengths and resilience in a dynamic healthcare landscape.
While challenges such as industry fluctuations and regulatory dynamics exist, McKesson's strategic positioning, diverse business lines, and growth opportunities position it for continued success.
By leveraging opportunities in service expansion, biosimilars, and market trends, McKesson aims to enhance patient outcomes, drive revenue growth, and maintain its leadership in the healthcare services sector.

McKesson exceeds Q1 expectations, focuses on supply chain efficiency

McKesson delivered strong first-quarter results, exceeding revenue and earnings expectations.
The company's focus on enhancing supply chain efficiency and expanding relationships with manufacturers is driving growth.
Challenges include non-linear investments and the impact of 340B on pharmaceutical distribution business.
Opportunities lie in benefiting from volume-related factors, supporting product life cycles, and expanding oncology solutions.

McKesson excels in Q2, anticipates growth amid strategic investments

McKesson's Q2 performance reflects strong revenue growth and operational excellence across key segments.
The company's focus on employee well-being, technology solutions, and strategic investments positions it for continued success.
While facing competitive challenges in generics procurement, McKesson maintains stability and customer-centric supply.
Anticipated growth opportunities in fiscal 2024 and beyond underscore McKesson's commitment to innovation and operational efficiency.

McKesson reports robust Q3 earnings, eyes growth through strategic investments

McKesson's Q3 performance reflects strong revenue and earnings growth, supported by strategic initiatives and investments in key segments. While facing challenges like patient visit volumes and margin pressures, the company remains focused on driving sustainable growth and value delivery. Opportunities for growth through technology investments and segment expansions position McKesson for future success.

McKesson reports robust Q4 results, eyes growth in oncology services

McKesson's strong performance in Q4 '24 underscores its leadership in oncology and biopharma services, supported by strategic investments in AI and a new partnership with Optum. While facing challenges in pricing dynamics and 3PL business growth, the company is well-positioned to capitalize on opportunities in inorganic growth, AI utilization, and health equity initiatives.

McKesson reports solid Q1 growth, focuses on pharma innovation

McKesson's Q1 2025 showed solid revenue growth and increased earnings per share, driven by strong performance in pharmaceutical segments.
While facing challenges in the Medical-Surgical segment, the company aims to leverage strengths in distribution and technology investments for future growth.
Opportunities lie in capitalizing on pharmaceutical segment performance and driving innovation through technology investments.
Overall, McKesson's outlook for fiscal 2025 remains positive with projected revenue and profit growth.

McKesson posts record revenue, focuses on oncology for sustained growth

McKesson's strong financial performance and raised guidance reflect its resilience and strategic focus on growth.
While facing regulatory and integration challenges, the company's commitment to innovation and employee well-being positions it well for the future.
Opportunities lie in expanding market presence through acquisitions, influencing policy reforms, and optimizing operational efficiencies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

McKesson Corp. engages in providing healthcare services. It operates through the following segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs. The RxTS segment offers prescription price transparency, benefit insight, dispensing support services, third-party logistics, and wholesale distribution. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The International segment refers to the distribution and services to wholesale, institutional, and retail customers in Europe and Canada. The company was founded by John McKesson and Charles Olcott in 1833 and is headquartered in Irving, TX.

CVS Health

Microsoft

Some of the world's most successful hedge fund managers are making big bets on these dividend payers.

3 Top Dividend Growth Stocks Billionaires Are Buying Hand Over Fist

AmerisourceBergen

Cardinal Health

This Buffett-backed business leads the medical distribution industry.

Is This Warren Buffett Stock a Buy for Dividend Growth Investors?

The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for MCL.

McKesson (MCK) Announces Availability of FDA-Cleared Drug for MCL

IRVING, Texas--(BUSINESS WIRE)--McKesson received approval from CMS to participate in the Merit-based Incentive Payment System (MIPS) as a Qualified Clinical Data Registry (QCDR).

McKesson Designated by CMS as 2023 Qualified Clinical Data Registry

Apple

Ally Financial

Activision Blizzard

Bank of New York Mellon

Chevron

Kroger

Louisiana-Pacific

Paramount Global

Taiwan Semiconductor Manufacturing

U.S. Bancorp

Buffett's company Berkshire Hathaway spent more time selling stocks than buying in the fourth quarter of 2022.

Warren Buffett Didn't Buy a Single New Stock to End 2022. But He Cut From 8.

Halliburton

Jabil

Digging into three highly-ranked stocks that outperformed the market in 2022 amid the turmoil and are primed to keep running higher in 2023 even if Wall Street is forced to take its foot off the growth pedal.

3 Highly-Ranked Stocks that Beat the Market in 2022 to Buy Now

The heavy selling pressure might have exhausted for McKesson (MCK) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Here's Why McKesson (MCK) is Poised for a Turnaround After Losing -6.24% in 4 Weeks

McKesson (MCK) could produce exceptional returns because of its solid growth attributes.

Is McKesson (MCK) a Solid Growth Stock? 3 Reasons to Think "Yes"

Labcorp Holdings Inc

Merit Medical Systems

Here, we discuss five stocks from the Dental Supplies industry that are likely to create wealth for investors - MCK, ABC, LH, CAH and MMSI.

5 Dental Supplies Stocks to Buy Amid Recovering Prospects

McKesson's (MCK) third-quarter fiscal 2023 results benefit from segmental growth.

McKesson (MCK) Q3 Earnings Surpass Estimates, EPS View Up

McKesson Corporation (NYSE:MCK ) Q3 2023 Results Conference Call February 1, 2023 4:30 PM ET Company Participants Rachel Rodriguez - VP, IR Brian Tyler - CEO Britt Vitalone - CFO Conference Call Participants Michael Cherny - Bank of America Merrill Lynch Lisa Gill - JPMorgan Eric Percher - Nephron Research Charles Rhyee - Cowen George Hill - Deutsche Bank Steven Valiquette - Barclays Brian Tanquilut - Jefferies LLC A.J. Rice - Credit Suisse Operator Welcome to McKesson's Third Quarter Fiscal 2023 Earnings Conference Call.

McKesson Corporation (MCK) Q3 2023 Earnings Call Transcript

McKesson (MCK) delivered earnings and revenue surprises of 8.83% and 0.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

McKesson (MCK) Tops Q3 Earnings and Revenue Estimates

IRVING, Texas--( BUSINESS WIRE )--McKesson Corporation (NYSE: MCK) has released its fiscal 2023 third-quarter financial results. Results can be accessed on McKesson's Investor Relations website at investor.mckesson.com/financials/quarterly-results.

McKesson Corporation Reports Fiscal 2023 Third-Quarter Results

Harmony Biosciences Holdings

Eli Lilly

Merck

Novo Nordisk

UnitedHealth Group

Vir Biotechnology

Healthcare stocks performed well in 2022, driven by a number of factors. One of the main drivers was the ongoing COVID-19 pandemic, which continued to boost demand for healthcare products and services.

7 Healthcare Stocks That Will Be Big Winners in 2023

Sanofi

There is a continued need for prosperous healthcare companies, here are two medical stocks investors may want to consider buying ahead of earnings this week.

2 Medical Stocks to Consider Buying Before Earnings

McKesson's (MCK) fiscal third-quarter results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.

McKesson (MCK) to Report Q3 Earnings: Is a Beat in the Cards?

Affiliated Managers

Enbridge

Fair Isaac

First Solar

Hanesbrands

Lamb Weston Hlds

Principal Financial Group

PennyMac Financial Services

The Federal Reserve has been aggressive in its rate hiking, and it's likely not done yet. Here are nine of the best stocks for rising interest rates.

9 Best Stocks for Rising Interest Rates

IRVING, Texas--( BUSINESS WIRE )--McKesson Corporation today announced that the company has received approval by the Science Based Targets initiative (SBTi) for its near-term climate change targets that contribute to reducing its Greenhouse Gas (GHG) emissions. McKesson joins more than 2,000 companies committed to setting and achieving targets to reduce GHG emissions that are aligned to the goal of limiting global temperature rise to 1.5°C.

McKesson Receives Approval of Its Near-term Climate Change Targets by the Globally Recognized Science Based Targets initiative

Amazon

Johnson & Johnson

Coca-Cola

Procter & Gamble

These stocks deliver a lot of the elements Buffett loves most.

5 Warren Buffett Stocks to Buy Hand Over Fist in 2023

Madrigal Pharmaceuticals

Vertex Pharmaceuticals

These healthcare stocks have a lot going for them in the new year.

3 Top Healthcare Stocks to Buy for January

HCA Healthcare

These Buffett stocks look like a bargain you won't want to miss.

My Favorite Warren Buffett Stocks for 2023

Advanced Micro Devices

Constellation Energy Corp

Enphase Energy

Netflix

Northrop Grumman

Stanley Black & Decker

V.F.

Cramer named 10 stocks listed in the S&P 500 that he believes could perform well this year.

Jim Cramer predicts these ten S&P 500 stocks will perform well in 2023

News for McKesson Stock (MCK)